Drug companies urged to make more use of UK regulator's ''broader scope'' scientific advice
This article was originally published in SRA
Executive Summary
Pharmaceutical companies in the UK are missing a trick by failing to take advantage of the “broader scope” scientific advice service that is on offer from the Medicines and Healthcare products Regulatory Agency. The UK R&D-based pharma industry association, the ABPI, said in response that it would always encourage companies to get scientific advice from the MHRA and would work with the agency to raise awareness of the scheme within the industry.
You may also be interested in...
EU Accelerated Assessment Tracker
Marinus’s ganaxolone has lost its accelerated assessment status mid-review at the European Medicines Agency while Roche’s glofitamab will be fast-tracked once a filing has been made.
EU Accelerated Assessment Tracker
The EU filing for AstraZeneca’s nirsevimab is being reviewed under the accelerated pathway at the European Medicines Agency. Also, Janssen should know by now whether its planned filing for Zejula plus Zytiga will get the same treatment – as should SIFI for its planned Akantior filing.
AZ Secures EU Fast-Tack Review For Nirsevimab
There could be a regulatory decision on AstraZeneca and Sanofi's nirsevimab in the EU in H2 as a result of the European Medicines Agency speeding up its review of the marketing application for the potential new immunization against RSV in all infants.